Ranked #1,756 of 8,699 institutional investors
Affinity Asset Advisors, LLC
New York, NY
$1.60B
US stock portfolio at live prices · today +$11.2M (+0.70%)
Market closed. Prices as of Nov 20, 7:11 AM ET
- Value at quarter end (Q3 2026)
- $1.72B
- Change from Q2 2026
- −$294.8M (−14.62%)
- Positions
- 84 · 18 new, 10 sold out
- Filed
- Nov 13, 2026
Not counted in the ranking: call options on $131M of stock, put options on $564M, $41.0M of convertible notes and other principal-amount securities. $277M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesSYRE 7.81%TRAX 5.78%INSM 5.10%ERAS 4.97%XENE 4.47%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| SYRE Spyre Therapeutics, Inc. | 1,279,134 | $125M | 7.81% | Unchanged |
| TRAX First Tracks Biotherapeutics, Inc. | 2,080,000 | $92.5M | 5.78% | Added +2% |
| INSM Insmed Incorporated | 564,251 | $81.5M | 5.10% | Reduced −13% |
| ERAS Erasca, Inc. | 5,590,600 | $79.5M | 4.97% | Added +6% |
| XENE Xenon Pharmaceuticals Inc. | 1,900,374 | $71.4M | 4.47% | Added +19% |
| ORKA Oruka Therapeutics, Inc. | 600,000 | $58.5M | 3.66% | Added +2% |
| PRAX Praxis Precision Medicines, Inc. | 155,000 | $48.2M | 3.01% | Reduced −16% |
| CYTK Cytokinetics, Incorporated | 750,000 | $38.6M | 2.41% | Added +36% |
| BLTE Belite Bio, Inc | 242,088 | $36.6M | 2.29% | Added +47% |
| RVMD Revolution Medicines, Inc. | 225,000 | $35.9M | 2.24% | Reduced −10% |
| CLDX Celldex Therapeutics, Inc. | 1,160,499 | $32.4M | 2.03% | Added +66% |
| DNTH Dianthus Therapeutics, Inc. | 350,000 | $29.7M | 1.86% | Reduced −13% |
| ABVX ABIVAX Société Anonyme | 330,000 | $26.6M | 1.66% | Unchanged |
| TRVI Trevi Therapeutics, Inc. | 1,800,172 | $24.7M | 1.55% | Unchanged |
| SGMT Sagimet Biosciences Inc. | 2,527,384 | $24.3M | 1.52% | Added +1% |
| OVID Ovid Therapeutics Inc. | 10,144,562 | $23.7M | 1.48% | Unchanged |
| ODTX Odyssey Therapeutics, Inc. | 1,260,000 | $23.1M | 1.45% | Added +64% |
| AVTX Avalo Therapeutics, Inc. | 3,244,861 | $21.9M | 1.37% | Added +12% |
| LXEO Lexeo Therapeutics, Inc. | 7,245,611 | $21.4M | 1.34% | Added +25% |
| PTGX Protagonist Therapeutics, Inc. | 172,125 | $21.3M | 1.34% | Unchanged |
| ARWR Arrowhead Pharmaceuticals, Inc. | 425,000 | $18.6M | 1.16% | Added +183% |
| ANRO Alto Neuroscience Inc | 643,343 | $17.1M | 1.07% | Reduced −24% |
| TYRA Tyra Biosciences, Inc. | 850,000 | $16.8M | 1.05% | Added +325% |
| COAG Hemab Therapeutics Holdings, Inc. | 420,000 | $16.7M | 1.05% | Added +204% |
| TVTX Travere Therapeutics, Inc. | 300,000 | $14.5M | 0.91% | Unchanged |
| ARVN Arvinas, Inc. | 2,050,000 | $13.8M | 0.86% | New |
| RLAY Relay Therapeutics, Inc. | 850,000 | $13.5M | 0.85% | Reduced −19% |
| NRIX Nurix Therapeutics, Inc. | 967,620 | $13.2M | 0.82% | Unchanged |
| SVRA Savara Inc. | 2,512,153 | $13.1M | 0.82% | Unchanged |
| MDGL Madrigal Pharmaceuticals, Inc. | 30,000 | $11.9M | 0.74% | Reduced −25% |
| VOGX Vogenx, Inc. | 915,000 | $11.7M | 0.73% | New |
| JBIO Jade Biosciences, Inc. | 760,350 | $11.5M | 0.72% | Reduced −10% |
| MLYS Mineralys Therapeutics, Inc. | 750,000 | $10.6M | 0.66% | Unchanged |
| EPRX Eupraxia Pharmaceuticals Inc. | 1,716,320 | $10.5M | 0.66% | Added +4% |
| STRO Sutro Biopharma, Inc. | 1,152,487 | $10.0M | 0.63% | Reduced −2% |
| MANE Veradermics Inc | 79,400 | $9.9M | 0.62% | Reduced −21% |
| BEAM Beam Therapeutics Inc. | 450,000 | $9.4M | 0.59% | New |
| KRSA Korsana Biosciences, Inc. | 263,106 | $9.3M | 0.58% | New |
| CLYM Climb Bio Inc | 972,000 | $9.0M | 0.56% | Unchanged |
| SLN Silence Therapeutics plc | 450,000 | $8.9M | 0.56% | New |
| PRLD Prelude Therapeutics Incorporated | 2,600,000 | $8.5M | 0.53% | New |
| CGEM Cullinan Therapeutics, Inc. | 875,760 | $7.9M | 0.50% | Unchanged |
| AMLX Amylyx Pharmaceuticals, Inc. | 300,000 | $7.9M | 0.49% | Added +203% |
| VRDN Viridian Therapeutics, Inc. | 250,000 | $7.9M | 0.49% | Unchanged |
| IBRX ImmunityBio, Inc. | 1,180,000 | $7.8M | 0.48% | New |
| ELVN Enliven Therapeutics, Inc. | 148,000 | $6.9M | 0.43% | Reduced −70% |
| VERA Vera Therapeutics, Inc. | 250,000 | $6.7M | 0.42% | Unchanged |
| KRRO Korro Bio, Inc. | 531,904 | $6.5M | 0.41% | Reduced −25% |
| XFOR X4 Pharmaceuticals, Inc. | 2,062,500 | $6.1M | 0.38% | Added +1,322% |
| AKTS Aktis Oncology, Inc. | 350,000 | $5.7M | 0.36% | New |
| IDYA IDEAYA Biosciences, Inc. | 200,000 | $5.2M | 0.33% | Reduced −50% |
| AVR Anteris Technologies Global Corp. | 912,397 | $4.6M | 0.29% | Unchanged |
| DTIL Precision BioSciences, Inc. | 646,576 | $4.5M | 0.28% | Unchanged |
| SABS SAB Biotherapeutics, Inc. | 1,525,000 | $4.4M | 0.28% | Unchanged |
| RZLT Rezolute, Inc. | 1,000,000 | $4.2M | 0.26% | Unchanged |
| TSHA Taysha Gene Therapies, Inc. | 1,000,000 | $3.8M | 0.24% | Reduced −43% |
| IRD Opus Genetics, Inc. | 900,000 | $3.7M | 0.23% | New |
| NTLA Intellia Therapeutics, Inc. | 350,000 | $3.3M | 0.21% | New |
| LTGO Latigo Biotherapeutics, Inc. | 250,000 | $3.3M | 0.21% | New |
| IBIO iBio, Inc. | 4,130,427 | $3.3M | 0.21% | Added +3% |
| IMVT Immunovant, Inc. | 100,000 | $3.3M | 0.20% | Unchanged |
| ANAB AnaptysBio, Inc. | 66,464 | $3.2M | 0.20% | Reduced −92% |
| CATX Perspective Therapeutics, Inc. | 3,988,744 | $3.1M | 0.20% | Reduced −5% |
| ARKG ARK Genomic Revolution ETF | 74,900 | $3.0M | 0.19% | New |
| EQ Equillium, Inc. | 2,613,954 | $2.9M | 0.18% | Reduced −36% |
| MBX MBX Biosciences, Inc. | 50,000 | $2.7M | 0.17% | Reduced −33% |
| CMPS COMPASS Pathways plc | 301,183 | $2.6M | 0.16% | Unchanged |
| SLDB Solid Biosciences Inc. | 400,000 | $2.6M | 0.16% | New |
| PMVP PMV Pharmaceuticals, Inc. | 1,750,000 | $2.3M | 0.14% | New |
| VRCA Verrica Pharmaceuticals Inc. | 688,654 | $2.0M | 0.12% | Reduced −3% |
| NXTC NextCure, Inc. | 291,960 | $2.0M | 0.12% | Added +596% |
| MGNX MacroGenics, Inc. | 953,979 | $1.9M | 0.12% | Reduced −22% |
| NMRA Neumora Therapeutics, Inc. | 4,500,000 | $1.6M | <0.1% | Added +320% |
| EIKN Eikon Therapeutics, Inc. | 298,001 | $1.4M | <0.1% | Added +204% |
| ANL Adlai Nortye Group Ltd. | 153,847 | $1.4M | <0.1% | Unchanged |
| FTH Faeth Therapeutics, Inc. | 144,404 | $1.3M | <0.1% | Unchanged |
| AVBP ArriVent BioPharma, Inc. | 100,000 | $1.1M | <0.1% | Reduced −20% |
| SPRO Spero Therapeutics, Inc. | 1,300,000 | $1.1M | <0.1% | New |
| GENB Generate Biomedicines, Inc. | 100,000 | $1.0M | <0.1% | Reduced −75% |
| LENZ LENZ Therapeutics, Inc. | 300,000 | $1.0M | <0.1% | Added +200% |
| SLS SELLAS Life Sciences Group, Inc. | 50,000 | $743K | <0.1% | New |
| FDMT 4D Molecular Therapeutics, Inc. | 50,000 | $536K | <0.1% | New |
| QTTB Q32 Bio Inc. | 27,777 | $236K | <0.1% | Unchanged |
| ENTA Enanta Pharmaceuticals, Inc. | 29,300 | $234K | <0.1% | New |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| COGT Cogent Biosciences, Inc. | 450,000 | $12.5M |
| ASMB Assembly Biosciences, Inc. | 190,000 | $4.3M |
| SGP SpyGlass Pharma, Inc. | 131,586 | $4.1M |
| ALEC Alector, Inc. | 1,510,000 | $3.5M |
| SPRB Spruce Biosciences, Inc. | 30,000 | $1.2M |
| ENGN enGene Therapeutics Inc. | 600,000 | $1.1M |
| OKUR OnKure Therapeutics, Inc. | 240,963 | $665K |
| BOLD Boundless Bio, Inc. | 250,000 | $595K |
| OBIO Orchestra BioMed Holdings, Inc. | 33,400 | $234K |
| KPTIQ Karyopharm Therapeutics Inc. | 312,500 | $11K |